Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refract...
Q2 2026
Aug 3, 2026
Q1 2026
Apr 30, 2026
FY 2025
Feb 26, 2026
Q4 2025
Q3 2025
Nov 3, 2025